Positive Linear Growth and Bone Responses to Growth Hormone Treatment in Children With Types III and IV Osteogenesis Imperfecta: High Predictive Value of the Carboxyterminal Propeptide of Type I Procollagen

Extreme short stature is a cardinal feature of severe osteogenesis imperfecta (OI), types III and IV. We conducted a treatment trial of growth hormone in children with OI and followed linear growth velocity, bone metabolism markers, histomorphometrics, and vertebral bone density. Twenty‐six children with types III and IV OI, ages 4.5–12 years, were treated with recombinant growth hormone (rGH), 0.1–0.2 IU/kg per day for 6 days/week, for at least 1 year. Length, insulin‐like growth factor (IGF‐I), insulin‐like growth factor binding protein (IGFBP‐3), bone metabolic markers, and vertebral bone density by DXA were evaluated at 6‐month intervals. An iliac crest biopsy was obtained at baseline and 12 months. Approximately one‐half of the treated OI children sustained a 50% or more increase in linear growth over their baseline growth rate. Most responders (10 of 14) had moderate type IV OI. All participants had positive IGF‐I, IGFBP‐3, osteocalcin, and bone‐specific alkaline phosphatase responses. Only the linear growth responders had a significant increase in vertebral DXA z‐score and a significant decrease in long bone fractures. After 1 year of treatment, responders' iliac crest biopsy showed significant increases in cancellous bone volume, trabecular number, and bone formation rate. Responders were distinguished from nonresponders by higher baseline carboxyterminal propeptide (PICP) values (p < 0.05), suggesting they have an intrinsically higher capacity for collagen production. The results show that growth hormone can cause a sustained increase in the linear growth rate of children with OI, despite the abnormal collagen in their bone matrix. In the first year of treatment, growth responders achieve increased bone formation rate and density, and decreased fracture rates. The baseline plasma concentration of PICP was an excellent predictor of positive response.

[1]  F. Diamond,et al.  6 Growth hormone neurosecretory dysfunction , 1986 .

[2]  R. García-mayor,et al.  Serum Insulin-Like Growth Factor (IGF) Binding Protein-3 and IGF-I Levels during Childhood and Adolescence. A Cross-Sectional Study , 1995, Pediatric Research.

[3]  G. Saggese,et al.  Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1 st year of life to adulthood and in metabolic bone diseases , 1992, European Journal of Pediatrics.

[4]  J. R. Bowen,et al.  Normative data for iliac bone histomorphometry in growing children. , 1992, Bone.

[5]  G. Saggese,et al.  Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. , 1993, The Journal of pediatrics.

[6]  J. Risteli,et al.  Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. , 1990, Clinical chemistry.

[7]  D. Sillence,et al.  Genetic heterogeneity in osteogenesis imperfecta. , 1979, Journal of medical genetics.

[8]  F. Diamond,et al.  Growth hormone neurosecretory dysfunction. , 2020, Clinics in endocrinology and metabolism.

[9]  L. Tatò,et al.  Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. , 1996, The Journal of pediatrics.

[10]  M. Knip,et al.  Collagen metabolites in the prediction of response to GH therapy in short children. , 1997, European journal of endocrinology.

[11]  F. Glorieux,et al.  Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. , 1998, The New England journal of medicine.

[12]  T. Stijnen,et al.  Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. , 1999, The Journal of clinical endocrinology and metabolism.

[13]  T. Nam,et al.  Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children. , 1993, The Journal of clinical endocrinology and metabolism.

[14]  E. Schönau,et al.  Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth‐promoting treatments in short normal children , 1996, Clinical endocrinology.

[15]  S. Kanzaki,et al.  Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype. , 1998, European journal of endocrinology.

[16]  S. Kanzaki,et al.  Molecular defects in achondroplasia and the effects of growth hormone treatment , 1999, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[17]  P. Esposito,et al.  Osteogenesis Imperfecta. , 1928, Proceedings of the Royal Society of Medicine.

[18]  F. Glorieux,et al.  Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. , 2000, Bone.

[19]  D. Cole,et al.  Serum osteocalcin concentrations in children with metabolic bone disease. , 1985, The Journal of pediatrics.

[20]  G. Chrousos,et al.  Endocrine aspects of growth deficiency in OI. , 1995, Connective tissue research.

[21]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  G. Chrousos,et al.  Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. , 1993, American journal of medical genetics.

[23]  F. Glorieux,et al.  Structural and cellular changes during bone growth in healthy children. , 2000, Bone.

[24]  P. Hindmarsh,et al.  Serum Concentrations of the Type I and III Procollagen Propeptides as Biochemical Markers of Growth Velocity in Healthy Infants and Children and in Children with Growth Disorders , 1991, Pediatric Research.

[25]  P. Robey,et al.  Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  J. Kopp,et al.  Osteogenesis imperfecta: Changes in noncollagenous proteins in bone , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  G. Saggese,et al.  Twenty-four-Hour Osteocalcin, Carboxyterminal Propeptide of Type I Procollagen, and Aminoterminal Propeptide of Type III Procollagen Rhythms in Normal and Growth-Retarded Children , 1994, Pediatric Research.

[28]  Z. Hochberg,et al.  Final height in young women with Turner syndrome after GH therapy: an open controlled study. , 1999, European journal of endocrinology.

[29]  P. Robey,et al.  Human bone cells in vitro. , 1985, Calcified tissue international.

[30]  G. Chrousos,et al.  The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. , 1993, The Journal of clinical endocrinology and metabolism.

[31]  W. Mendelson,et al.  Growth hormone neurosecretory dysfunction. A treatable cause of short stature. , 1984, JAMA.